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ABSTRACT: A series of dinuclear octahedral PtIV complexes
trans,trans,trans-[{Pt(N3)2(py)2(OH)(OC(O)CH2CH2C(O)-
NH)}2R] containing pyridine (py) and bridging dicarboxylate [R =
−CH2CH2− (1), trans-1,2-C6H10− (2), p-C6H4− (3),
−CH2CH2CH2CH2− (4)] ligands have been synthesized and
characterized, including the X-ray crystal structures of complexes 1·
2MeOH and 4, the ﬁrst photoactivatable dinuclear PtIV complexes
with azido ligands. The complexes are highly stable in the dark, but
upon photoactivation with blue light (420 nm), they release the
bridging ligand and mononuclear photoproducts. Upon irradiation
with blue light (465 nm), they generate azidyl and hydroxyl radicals,
detected using a 5,5-dimethyl-1-pyrroline N-oxide electron para-
magnetic resonance spin trap, accompanied by the disappearance of the ligand-to-metal charge-transfer (N3 → Pt) band at ca.
300 nm. The dinuclear complexes are photocytotoxic to human cancer cells (465 nm, 4.8 mW/cm2, 1 h), including A2780
human ovarian and esophageal OE19 cells with IC50 values of 8.8−78.3 μM, whereas cisplatin is inactive under these conditions.
Complexes 1, 3, and 4 are notably more photoactive toward cisplatin-resistant ovarian A2780cis compared to A2780 cells.
Remarkably, all of the complexes were relatively nontoxic toward normal cells (MRC5 lung ﬁbroblasts), with IC50 values >100
μM, even after irradiation. The introduction of an aromatic bridging ligand (3) signiﬁcantly enhanced cellular uptake. The
populations in the stages of the cell cycle remained unchanged upon treatment with complexes in the dark, while the population
of the G2/M phase increased upon irradiation, suggesting that DNA is a target for these photoactivated dinuclear PtIV
complexes. Liquid chromatography−mass spectrometry data show that the photodecomposition pathway of the dinuclear
complexes results in the release of two molecules of mononuclear platinum(II) species. As a consequence, DNA binding of the
dinuclear complexes after photoactivation in cell-free media is, in several respects, qualitatively similar to that of the
photoactivated mononuclear complex FM-190. After photoactivation, they were 2-fold more eﬀective in quenching the
ﬂuorescence of EtBr bound to DNA, forming DNA interstrand cross-links and unwinding DNA compared to the photoactivated
FM-190.
■ INTRODUCTION
Photoactivation is a promising eﬀective and noninvasive
chemotherapeutic strategy.1−4 Photochemotherapy using the
appropriate Pt complexes has the potential to overcome some
of the limitations of conventional cisplatin therapy, including
poor pharmacokinetics, dose-limiting side eﬀects, restricted
spectrum of anticancer activity, high incidence of resistance,
and lack of normal-cell discrimination.5,6 The application of
O2-dependent photodynamic therapy is limited because of the
low concentration of O2 in hypoxic tumors, together with the
need for diﬀusion of O2 from adjacent tissues.
7 Photoactivated
chemotherapy, in contrast, is less dependent on O2 for
cytotoxicity and provides a new avenue to anticancer drug
design.
Octahedral, low-spin 5d6 PtIV complexes are usually
considered to be prodrugs because they are kinetically more
inert than their PtII counterparts under biological condi-
tions.8−10 Photoactivatable PtIV prodrugs can exhibit high dark
stability and potential photocytotoxicity;11−13 examples
include diazidoplatinum(IV) complexes containing various
nonleaving amines and axial substituents.14−20 Among them,
trans,trans,trans-[Pt(N3)2(OH)2(py)2] (FM-190) is highly
potent,21,22 has good aqueous solubility, is relatively stable in
cell culture media and toward reactions with abundant
intracellular tripeptide glutathione (GSH; γ-L-Glu-L-Cys-Gly),
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and can be activated by UVA, blue (420 nm) and green (500
± 30 nm) light, achieving low micromolar IC50 values even in
cisplatin-resistant cell lines, with a high phototoxicity index.
Not only does the Pt center become reactive upon photo-
reduction, but, in addition, azidyl radicals can be released by
FM-190 in a manner controllable by the amino acid L-Trp.23
Axial ligands in diazidoplatinum(IV) complexes normally act
as leaving groups upon reduction to PtII and greatly inﬂuence
the reduction potential of PtIV. Derivatization of an axial ligand
can be used to improve the pharmacological properties without
interfering with the ultimate mode of action of the active PtII
species or the potential production of other reactive species.
Several studies have been carried out previously on the
conjugation of FM-190 to functional fragments, including αvβ3
and αvβ5 integrin-selective arginine−glycine−aspartic acid-
(RGD)-containing peptides,24 RNA-binding guanidinoneomy-
cin,25 2,2,6,6-tetramethylpiperidin-1-yl)oxyl (TEMPO) radi-
cal,26 upconversion-luminescent nanoparticles,27 and G-quad-
ruplex G4K
+ borate hydrogels.28 For the former two
conjugates, the selectivity and cellular uptake toward speciﬁc
cancer cells was remarkably enhanced, while for the prodrug
with TEMPO, azidyl and TEMPO radicals were released upon
irradiation with blue light (420 nm), accompanied by the
formation of toxic PtII species, resulting in improved
cytotoxicity. Upconversion-luminescent nanoparticles enable
photoactivation with near-IR light, and hydrogels allow the
treatment of surface cancers with minimal damage to normal
tissues.
Polynuclear Pt complexes have attracted much attention
because of their unique biological properties, including
coordinative binding to DNA bases and interaction of the
phosphodiester linker through electrostatic and hydrogen-
bonding eﬀects.29 The preassociation of polynuclear Pt
complexes with DNA prior to coordinate bond formation
can signiﬁcantly aﬀect the kinetics of cross-link formation,30−33
which distinguishes them from their mononuclear counter-
parts. The trinuclear complex [{trans-PtCl(NH3)2}2(μ-trans-
Pt(NH3)2{NH2(CH2)6NH2}2)]
4+ (BBR3464) underwent
phase I and II human clinical trials as a promising anticancer
Pt drug.34−36
In order to investigate the structure−activity relationships
related to modiﬁcation of the axial ligands of diazidoplatinum-
(IV) complexes and improve the antiproliferative activity of
photoactivatable PtIV prodrugs, we synthesized and charac-
terized a series of dinuclear PtIV complexes of the type
trans,trans,trans-[{Pt(N3)2(py)2(OH)(OC(O)CH2CH2C(O)-
NH)}2R] [R = −CH2CH2− (1), trans-1,2-C6H10− (2), p-
C6H4− (3), −CH2CH2CH2CH2− (4)]. The X-ray crystal
structures of complexes 1·2MeOH and 4 were determined.
These appear to be the ﬁrst photoactivatable dinuclear PtIV
complexes containing azides to be reported. Their photo-
decomposition, photoreactions with 5′-guanosine monophos-
phate (5′-GMP), interaction with DNA, photocytotoxicity,
cellular accumulation, and eﬀect on the cancer cell cycle
distribution were studied. The chemical and biological
behavior of these complexes containing two Pt centers and
four azides in one molecule are compared to related
mononuclear diazido complexes, including the inﬂuence of
the nature of the bridging ligand.
■ EXPERIMENTAL SECTION
Materials and Instruments. O-(Benzotriazol-1-yl)-N,N,N′,N′-
tetramethyluronium tetraﬂuoroborate (TBTU) was purchased from
Merck. Pyridine was purchased from Fischer Scientiﬁc UK. Calf
thymus DNA (ct-DNA), K2PtCl4, NaN3, H2O2 (30%), succinic
anhydride, and other chemicals were purchased from Sigma-Aldrich
and used without further puriﬁcation.
NMR spectra were recorded on Bruker Avance III HD 400 MHz
and Bruker 500 MHz spectrometers; the residual signal of the solvent
was used as a reference. Electrospray ionization mass spectrometry
(ESI-MS) spectra were recorded on an Agilent 6130B single
quadrupole detector instrument, and high-resolution ESI-MS data
were collected on a Bruker microTOF instrument at 298 K with a
scan range of m/z 50−2000 for positive ions. Samples were prepared
in methanol or aqueous solution. Electronic absorption spectra were
recorded on a Varian Cary 300 UV−vis spectrophotometer in a quartz
cuvette and referenced to neat solvent. The spectral width was 200−
800 nm, the bandwidth was 1.0 nm, and the scan rate was set to 600
nm/min. Analytical reversed-phase high-performance liquid chroma-
tography (HPLC) analyses were carried out on an Agilent ZORBAX
Eclipse XDB-C18 column (250 × 4.6 mm, 5 μm, ﬂow rate 1 mL/min)
by using linear gradients of 0.1% triﬂuoroacetic acid (TFA) in water
(solvent A) and 0.1% TFA in acetonitrile (solvent B). Liquid
chromatography−mass spectrometry (LC−MS) was carried out on a
Bruker Amazon X connected online with HPLC. The light sources
used for photoactivation were an LZC-ICH2 photoreactor (Luzchem
Research Inc.) equipped with a temperature controller, eight Luzchem
LZC-420 lamps without light ﬁltration, and a KiloArcTM broad-band
arc lamp monochromator supplied with the appropriate ﬁlters to cut
oﬀ any unwanted light. A light-emitting-diode (LED) light source
with λmax = 465 nm was used for in vitro growth inhibition and cell
cycle assays. Platinum contents were analyzed on a 5300DV
inductively coupled plasma optical emission spectrometer (ICP-
OES, PerkinElmer) or a 7500cx inductively coupled plasma mass
spectrometer (ICP-MS, Agilent). The emission wavelengths detected
for Pt were 265.945, 214.423, 299.797, 204.937, and 193.700 nm.
Synthesis and Characterization. Caution! Heavy-metal azides
can be shock-sensitive detonators. We did not encounter any problems
during the work reported here, but due care and attention with
appropriate precautions should be taken in their synthesis and handling.
All synthesis and purif ications were carried out in the dark with minimal
light exposure.
General Synthesis Procedure for Complexes 1−4. To a solution
of trans,trans,trans-[Pt(N3)2(OH)(succinate)(py)2] (24.4 mg, 42.8
μmol) and TBTU (11.8 mg, 36.8 μmol) in freshly degassed
anhydrous N,N-dimethylformamide (DMF; 2 mL) N,N-diisopropy-
lethylamine (DIPEA; 100 μL) was added. After stirring for 3 min, a
solution of 0.5 mol equiv of the corresponding diamine, DIPEA (60
μL) and DMF (1 mL), was added to the resulting mixture dropwise.
The reaction mixture was stirred overnight at 298 K under a N2
atmosphere. After evaporation to dryness, the oily residue was
collected and puriﬁed by column chromatography on aluminum oxide
(5% methanol + 95% dichloromethane).
trans,trans,trans-[{Pt(N3)2(py)2(OH)(OC(O)CH2CH2C(O)-
NH)}2(CH2)2] (1). Diamine = ethylenediamine.
1H NMR (DMSO-d6,
400 MHz): δ 8.81 (dd, J = 5.5 Hz, J195Pt−1H = 26.6 Hz, 8H, Hα py),
8.26 (t, J = 7.5 Hz, 4H, Hγ py), 7.82 (t, J = 7.0 Hz, 8H, Hβ py), 7.75
(t, J = 5.7 Hz, 2H, CONH), 3.66 (s, 2H, OH), 3.05 (s, 4H, CH2), 2.46
(t, J = 7.6 Hz, 4H, CH2), 2.22 (t, J = 7.3 Hz, 4H, CH2).
13C NMR
(DMSO-d6, 125 MHz): δ 175.27 (COO), 172.08 (CONH), 149.83
(Cαpy), 142.42 (Cγ py), 126.66 (Cβ py), 38.80 (CH2), 32.39 (CH2),
32.21 (CH2). ESI-MS (M + Na
+): m/z 1189.2160. Anal. Calcd for
C30H36N18O8Pt2: C, 30.88; H, 3.11; N, 21.61. Found: C, 30.43; H,
3.10; N, 20.69.
trans,trans,trans-[{Pt(N3)2(py)2(OH)(OC(O)CH2CH2C(O)-
NH)}2(trans-1,2-C6H10)] (2). Diamine = trans-1,2-cyclohexanediamine.
1H NMR (DMSO-d6, 400 MHz): δ 8.82 (dd, J = 5.5 Hz, J195Pt−1H =
26.5 Hz, 8H, Hα py), 8.25 (t, J = 7.5 Hz, 4H, Hγ py), 7.82 (t, J = 6.9
Hz, 8H, Hβ py), 7.52 (d, J = 7.3 Hz, 2H, CONH), 3.66 (s, 2H, OH),
3.47 (s, 2H, CH2 cyclohexyl), 2.48−2.33 (m, 4H, CH2), 2.26−2.10
(m, 4H, CH2), 1.74 (s, 2H, CH2 cyclohexyl), 1.62 (s, 2H, CH2
cyclohexyl), 1.18 (s, 4H, CH2 cyclohexyl).
13C NMR (DMSO-d6, 125
MHz): δ 175.23 (COO), 171.68 (CONH), 149.84 (Cα py), 142.38
Inorganic Chemistry Article
DOI: 10.1021/acs.inorgchem.8b02599
Inorg. Chem. 2018, 57, 14409−14420
14410
(Cγ py), 126.65 (Cβ py), 55.38 (CH2 cyclohexyl), 52.50 (CH
cyclohexyl), 49.06 (CH cyclohexyl), 32.74 (CH2), 32.58 (CH2), 32.10
(CH2 cyclohexyl), 24.87 (CH2 cyclohexyl). ESI-MS (M + Na
+): m/z
1243.2631. Anal. Calcd for C34H42N18O8Pt2: C, 33.45; H, 3.47; N,
20.65. Found: C, 33.84; H, 3.48; N, 19.14.
trans,trans,trans-[{Pt(N3)2(py)2(OH)(OC(O)CH2CH2C(O)NH)}2(1,4-
C6H4)] (3). Diamine = p-phenylenediamine.
1H NMR (DMSO-d6, 400
MHz): δ 9.79 (s, 2H, CONH), 8.82 (dd, J = 5.5 Hz, J195Pt−1H = 26.7
Hz, 8H, Hα py), 8.25 (t, J = 7.3 Hz, 4H, Hγ py), 7.79 (t, J = 7.1 Hz,
8H, Hβ py), 7.50 (s, 4H, CH benzyl), 3.67 (s, 2H, OH), 2.67 (t, J =
7.3 Hz, 4H, CH2), 2.33 (t, J = 7.6 Hz, 4H, CH2).
13C NMR (DMSO-
d6, 125 MHz): δ 175.20 (COO), 170.71 (CONH), 149.83 (Cα py),
142.39 (Cγ py), 135.10 (C benzyl), 126.64 (Cβ py), 119.77 (CH
benzyl), 33.09 (CH2), 32.13 (CH2). ESI-MS (M + Na
+): m/z
1237.2138. Anal. Calcd for C34H36N18O8Pt2·Et2O: C, 35.41; H, 3.60;
N, 19.56. Found: C, 35.54; H, 3.76; N, 19.96
trans,trans,trans-[{Pt(N3)2(py)2(OH)(OC(O)CH2CH2C(O)-
NH)}2(CH2)4] (4). Diamine = 1,4-butylenediamine.
1H NMR (DMSO-
d6, 400 MHz): δ 8.82 (dd, J = 5.5 Hz, J195Pt−1H = 26.9 Hz, 8H, Hα py),
8.27 (t, J = 7.6 Hz, 4H, Hγ py), 7.83 (t, J = 7.0 Hz, 8H, Hβ py), 7.71
(t, J = 5.5 Hz, 2H, CONH), 3.65 (s, 2H, OH), 3.00 (m, 4H, CH2),
2.45 (t, J = 7.3 Hz, 4H, CH2), 2.23 (t, J = 7.4 Hz, 4H, CH2), 1.34 (s,
4H, CH2).
13C NMR (DMSO-d6, 125 MHz): δ 175.28 (COO),
171.72 (CONH), 149.84 (Cα py), 142.41 (Cγ py), 126.66 (Cβ py),
38.69 (CH2), 32.51 (CH2), 32.21 (CH2), 27.10 (CH2). ESI-MS (M +
Na+): m/z 1217.2461. Anal. Calcd for C32H40N18O8Pt2: C, 32.16; H,
3.37; N, 21.10. Found: C, 32.44; H, 3.36; N, 20.30.
X-ray Crystallography. Single crystals of 1·2MeOH and 4 were
grown from methanol/ether at ambient crystal was selected and
mounted on a Mitegen head with Fomblin oil and placed on an
Xcalibur Gemini diﬀractometer with a Ruby charge-coupled-device
(CCD) area detector. The crystal was kept at 150(2) K during data
collection. Using Olex2,37 the structure was solved with the ShelXT38
structure solution program using intrinsic phasing and reﬁned with
the ShelXL39 reﬁnement package using least-squares minimization.
Photodecomposition in Aqueous Solution. Photodecomposi-
tion of complexes 1−4 in aqueous solution was monitored by UV−vis
spectroscopy or LC−MS at diﬀerent time intervals after irradiation
with blue light (420 nm) at ambient temperature.
Cell Culture. A number of human cell lines, parental (A2780) and
cisplatin-resistant (A2780cis) ovarian carcinoma, esophageal adeno-
carcinoma (OE19), and normal ﬁbroblast cells (MRC5), were
obtained from the European Collection of Animal Cell Culture,
Salisbury, U.K. All cell lines used in this work were grown in Roswell
Park Memorial Institute media (RPMI-1640), which was supple-
mented with 10% (v/v) of fetal calf serum, 1% (v/v) of 2 mM
glutamine, and 1% (v/v) penicillin/streptomycin. The adherent
monolayers of cells were grown at 310 K in a humidiﬁed atmosphere
containing 5% CO2 and passaged regularly at ca. 80% conﬂuence.
Photo/dark Cytotoxicity. Approximately 10000 cells were
seeded per well in 96-well plates. Independent duplicate plates were
used, one for dark experiments and the other for irradiation
experiments. Complexes were ﬁrst dissolved in dimethyl sulfoxide
(DMSO) and then diluted in phenol-red-free RPMI-1640 to make the
stock solution of the drug. These stock solutions were further diluted
using a phenol-red-free cell culture medium until working
concentrations were achieved, in these solutions, the maximum
DMSO concentration was in all cases <0.5% (v/v). Cells were
exposed to the drugs with diﬀerent concentrations for 1 h. Then one
plate was irradiated for 1 h using blue light (4.8 mW cm−2 per LED at
465 nm), while the dark plate was kept in the incubator. After
irradiation, supernatants of both plates were removed by suction and
washed with a phosphate-buﬀered saline (PBS) buﬀer. The
photocytotoxicity was determined after another 24 h of recovery at
310 K in a drug-free phenol-red-containing medium by comparison to
untreated controls, which were only exposed to a vehicle. Untreated
controls were also compared between the irradiated and nonirradiated
plates to ensure that the diﬀerences in cell survival were not
statistically relevant, hence guaranteeing that the diﬀerences in cell
viability observed were not due to the light source. Sulforhodamine B
(SRB) assay was used to determine the cell viability.40 Absorbance
measurements of the solubilized dye (on a Promega microplate
reader, 510 nm) allowed the determination of viable treated cells
compared to untreated controls. The IC50 values (concentrations that
caused 50% of cell death) were determined as the average of
triplicates, and their standard deviations were calculated. Stock
concentrations for all metal complexes used in these biological assays
were adjusted/veriﬁed after ICP-OES metal quantiﬁcation.
Pt Accumulation in Cancer Cells. For Pt cellular accumulation
studies, ca. 4.5 × 106 A2780, A2780cis, and OE19 cells were plated in
100 mm Petri dishes and allowed to attach for 24 h. Then the plates
were exposed to complexes at equipotent concentrations equal to the
photoactive IC50 values in the corresponding cell line. Additional
plates were incubated with a medium alone as a negative control.
After 1 h of incubation in the dark at 310 K, the cells were rinsed
three times with cold PBS and harvested by trypsinization. The
number of cells in each sample was counted manually using a
hemocytometer. Then the cells were centrifuged to obtain the whole
cell pellet for ICP-MS analysis. All experiments were conducted in
triplicate.
ICP-MS Sample Preparation. The whole cell pellets were
dissolved in concentrated 72% (v/v) nitric acid (200 μL), and the
samples were then transferred into Wheaton V vials (Sigma-Aldrich)
and heated in an oven at 343 K overnight. The vials were then
allowed to cool, and each cellular sample solution was transferred into
a vial and diluted with Milli-Q water (3.8 mL) to obtain a ﬁnal HNO3
concentration of ca. 3.6% (v/v).
Photoreactions with 5′-GMP. An amount of 2, 4, or 8 mol equiv
of 5′-guanosine monophosphate disodium salt hydrate (5′-GMP-Na2)
was mixed with 30 μM complex 4 in 5:95 (v/v) methanol/water. The
solution was incubated at 310 K for 1 h, then irradiated for 1 h, and
analyzed immediately. HPLC analysis was carried out on an Agilent
ZORBAX Eclipse XDB-C18 column (250 × 4.6 mm, 5 μm, ﬂow rate
1 mL/min). The mobile phases for HPLC were A (0.1% formic acid
in HPLC-grade water, volume percentage) and B (0.1% formic acid in
HPLC-grade acetonitrile, volume percentage). The Pt adducts were
isolated and analyzed by a Bruker Amazon X connected online with
the high-performance liquid chromatography (HPLC).
Electron Paramagnetic Resonance (EPR) Spectroscopy. The
EPR spectra were recorded on a Bruker EMX (X-band) spectrometer
at 298 K. Samples (ca. 100 μL) in aqueous solution were prepared,
transferred using a plastic syringe with metal needle to a standard
quality quartz tube with an inner diameter of 1.0 mm and an outer
diameter of 2.0 mm (Wilmad LabGlass), and sealed with paraﬁlm. A
y-incremental sweep mode of 120 with an accumulation of ﬁve scans
in the x dimensions was used. Typical key EPR spectrometer settings
were 2.0 G modulation amplitude, 1.37 mW microwave power, 1.0 ×
105 receiver gain, 5.12 ms conversion time, 5.12 ms time constant, and
200 G sweep width. The LED465E light irradiation source was
mounted within the EPR magnet, supported by a foam sponge, to
maintain its position throughout the EPR measurements. The
distance from the tip of the irradiation light bulb to the EPR cavity
was ca. 3 cm. Data were processed by Matlab R2016b with Easyspin
5.1.12 through a multicomponent ﬁt.
Flow Cytometry. All ﬂow cytometry experiments were carried out
using a Becton Dickinson FACScan ﬂow cytometer in the School of
Life Sciences at Warwick University. Typically, cells were seeded in 6-
well plates using 1.5 × 106 cells/well. Experiments included 24 h of
preincubation in drug-free media at 310 K in a CO2 humidiﬁed
atmosphere, followed by 1 h of drug exposure under the same
conditions. After this, samples were irradiated for 1 h. For
comparison, the dark plates were kept in the incubator for another
1 h. Supernatants were removed, cells were washed with PBS. Samples
were then collected after trypsinization, washed with PBS, and stained
in the dark with a mixture of propidium iodide and RNase. After 30
min of staining, the cell samples were washed and set up for ﬂow
cytometry reading on the red channel FL-2.
Kinetics of Binding to ct-DNA. ct-DNA was mixed with
complexes in 10 mM NaClO4, immediately irradiated (visible light,
λmax = 455 nm) for 60 or 120 min, and then kept at 310 K in the dark.
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The ri value was 0.05−0.08. Aliquots were removed at various time
intervals and quickly ﬁltered using a Sephadex G-50 column to
remove free (unbound) Pt. The Pt content in these DNA samples (rb,
deﬁned as the number of the molecules of the Pt complex coordinated
per nucleotide residue) was determined by atomic absorption
spectroscopy (AAS) and the concentration of DNA by UV−vis
spectroscopy.
Characterization of DNA Adducts of Photoactivated
Complexes by EtBr Fluorescence. ct-DNA was incubated with
the Pt complexes under irradiation conditions (visible light, λmax =
455 nm for 2 h and subsequently incubated in the dark for an
additional 23 h) at various rb values in 10 mM NaClO4 at 310 K.
Fluorescence measurements of ct-DNA modiﬁed by Pt complexes in
the presence of EtBr were performed at an excitation wavelength of
546 nm, and the emitted ﬂuorescence was analyzed at 590 nm. The
ﬂuorescence intensity was measured in NaCl (0.4 M) to avoid
secondary binding of EtBr to DNA. The concentrations were 0.01
mg/mL for DNA and 0.04 mg/mL for EtBr, which corresponded to
the saturation of all binding sites for EtBr in DNA. The ﬂuorescence
spectra were recorded by a Varian Cary Eclipse spectroﬂuoropho-
tometer using a 0.5 cm quartz cell at room temperature.
Formation of Interstrand Cross-links. Solutions of the plasmid
pUC19 linearized by EcoRI (50 μg/mL) were incubated with the Pt
complex under irradiation conditions (for 1 h and subsequently
incubated in the dark for an additional 23 h) at various ri values in
NaClO4 (10 mM) at 310 K. Autoradiograms were recorded of
denaturing 1% agarose gel of linearized DNA, which was 3′-end-
labeled and nonmodiﬁed or modiﬁed by FM-190, 1, and 4
photoactivated by visible light.
Transcription Mapping of Pt-DNA Adducts. Transcription of
the (NdeI/HpaI) restriction fragment of pSP73KB DNA modiﬁed by
cisplatin, transplatin, or 1, 4, and FM-190 in the dark or
photoactivated by visible light (λmax = 455 nm for 1 h and
subsequently incubated 23 h in the dark, 310 K, 10 mM NaClO4)
with DNA-dependent T7 RNA polymerase and electrophoretic
analysis of the transcripts was performed according to the protocols
recommended by the manufacturer (Promega Protocols and
Applications, 43−46, 1989/90) and described in detail previously.19
The concentration of DNA in this assay was 1.54 × 10−4 M (relative
to the monomeric nucleotide content). The ri values for platination
reactions were chosen so as to obtain an rb value in the range 0.001−
0.01. Pt complexes not bound to DNA were removed by ethanol
precipitation.
Unwinding of Negatively Supercoiled DNA. Negatively
supercoiled pSP73KB plasmid was treated with FM-190, 1, or 4,
photoactivated by visible light (λ = 420 nm) for 1 h, and incubated for
23 h at 310 K in the dark. The degree of supercoiling was monitored
using electrophoresis in 1% native agarose gel. The unwinding angle is
given by Φ = −18σ/rb(c), where σ is the superhelical density
(−0.063) and rb(c) is the value of rb at which the supercoiled and
nicked forms comigrate.
DNase I Footprinting. Supercoiled pSP73 plasmid was digested
with HindIII restriction endonuclease and 3′-end-labeled by treatment
with Klenow exo- and [α-32P]-deoxy-ATP. After radioactive labeling,
the DNA ﬁrst cleaved with HindIII was further digested with NdeI to
yield 158 and 2306 base-pair (bp) fragments. The 158 bp fragment
was puriﬁed by 1% agarose gel electrophoresis and isolated from the
gel by a Promega Wizard SV Gel cleanup system.
Radioactively labeled DNA (5.4 × 10−6 M) and the Pt complex (ri
= 0.1, 0.2, and 0.4) in 10 mM NaClO4 were irradiated by λ = 420 nm
for 1 h and incubated for 23 h at 310 K in the dark. Radioactively
labeled DNA and the Pt complex at ri = 0.4 were also incubated in the
dark for 24 h at 310 K. The reaction mixture was then lyophilized and
dissolved in a 9 μL solution containing a 1.11 × TKMC buﬀer (10
mM Tris, pH 7.9, 10 mM KCl, 10 mM MgCl2, and 5 mM CaCl2) and
3 μg of ct-DNA. Cleavage was initiated by the addition of 0.25 U of
DNase I (one unit of RQ1 RNase-free DNase is deﬁned as the
amount required to completely degrade 1 μg of lambda DNA in 10
min at 310 K in 50 μL of a buﬀer containing 40 mM Tris-HCl (pH
7.9), 10 mM NaCl, 6 mM MgCl2, and 10 mM CaCl2) and allowed to
react for 30 s at 298 K before quenching with 2.5 μL of a DNase stop
solution (3 M NaOAc and 0.25 M ethylenediaminetetraacetic acid).
This was then precipitated with ethanol, lyophilized, and resuspended
in a formamide loading buﬀer. DNA cleavage products were resolved
by poly(acrylamide) (PAA) gel electrophoresis under denaturing
conditions (8%/8 M urea PAA gel). The autoradiograms were
visualized and quantiﬁed by using a bioimaging analyzer. Assignment
of the cleavage to a particular base has been made so that it
corresponds to cleavage of the phosphodiesteric bond on the 5′ side
of that base.
■ RESULTS AND DISCUSSION
Synthesis and Characterization of Complexes 1−4.
The synthetic route for dinuclear PtIV complexes 1−4 is
summarized in Scheme 1. The mononuclear complexes
trans,trans,trans-[Pt(N3)2(OH)2(py)2] (FM-190) and trans,-
trans,trans-[Pt(N3)2(OH)(OC(O)CH2CH2C(O)OH)(py)2]
(FMSA) were prepared by procedures similar to those
reported.26 The two PtIV centers with axial succinate
carboxylates were coupled through amide bond formation
using bridging diamines containing ethylene (1), 1,2-cyclo-
hexyl (2), 1,4-phenylene (3), or butyl (4) linkers. Complexes
1−4 are air-stable at ambient temperature, both in the solid
state and in aqueous solution. They gave satisfactory elemental
analysis and were further characterized by ESI-MS, NMR, and
UV−vis spectroscopy and, for complexes 1 and 4, by X-ray
crystallography.
The 1H and 13C NMR spectra of complexes 1−4 in DMSO-
d6 contain the expected peaks (Figures S1−S8). In the 1H
NMR spectra, the doublets with 195Pt satellites at ca. 8.82 ppm
(J = 5.5 Hz; J195Pt−1H = 26.6 Hz) and the triplets at ca. 8.26 ppm
(J = 7.5 Hz) and 7.82 ppm (J = 7.0 Hz) are assigned to the Hα,
Hγ, and Hβ of pyridine, respectively. The peaks at ca. 3.66 ppm
are assignable to the resonances of the hydroxyl protons and
the peaks at 7.52−9.79 ppm to the amide protons. The 13C
Scheme 1. Synthetic Route for Photoactive Dinuclear Diazidoplatinum(IV) Complexes 1−4
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NMR resonances of complexes 1−4 at ca. 149.83, 142.40, and
126.66 ppm are attributable to the Cα, Cγ, and Cβ of pyridine,
respectively. The complexes all display peaks at ca. 175.27 and
172.00 ppm for the carboxyl and amide C atoms, respectively.
The electronic absorption spectrum of complex 1 is similar to
that of its mononuclear analogue FM-190. In a water/
methanol (2:3) solution, complex 1 shows a high-energy
band at 262 nm (ε = 25260 M−1 cm−1) and a maximum
absorption band at 300 nm (34109 M−1 cm−1), which are
assigned to a ligand-to-metal charge-transfer (LMCT; OH →
Pt and N3 → Pt) transition. In addition, a weak band is
observed at 420 nm that has mixed 1LMCT/1IL (interligand)
character and involves N3 and OH ligands and Pt.
21 This band
enables the photoactivation of complex 1 using blue light.
Complexes 2−4 show electronic absorption spectra similar to
that of complex 1, except that the high-energy band (at 260
nm, ε = 49189 M−1 cm−1) of complex 3 is more intense than
those of its analogues (ε ≈ 25000 M−1 cm−1) because of
absorption of the phenyl fragment.
X-ray Crystallography. Crystals suitable for X-ray
diﬀraction studies of complexes 1·2MeOH and 4 were
obtained through the diﬀusion of diethyl ether into
corresponding solutions in methanol. The structures of
complexes 1·2MeOH and 4 are shown in Figure 1. The
crystallographic data are summarized in Table S1, and selected
bond distances and angles are listed in Table 1. Complex 1·
2MeOH crystallized in the triclinic space group P1̅ with one
complex and two methanol molecules in the unit cell. Complex
4 crystallized in the monoclinic space group P21/n with two
molecules in the unit cell.
Complexes 1·2MeOH and 4 are neutral and consist of two
mononuclear PtIV fragments bridged by an aliphatic linker of a
diamine that forms amide bonds to the axial succinate
carboxylates. The two Pt centers are symmetric, with the
diamine linker sitting on an inversion center. The geometries
of the Pt centers are similar to that of their mononuclear
analogue FM-190: octahedral with [N4O2] coordination. The
equatorial plane is deﬁned by four N atoms, two from the
trans-pyridine molecules and two from the trans-azides. An O
atom from a hydroxido ligand is located in an axial position,
while the other axial position is occupied by an O atom from
one of the succinate carboxylate groups.
Figure 1. X-ray crystal structures of 1·2MeOH (A) and 4 (B). The complexes sit on inversion centers, and only key atoms are labeled. Thermal
ellipsoids are drawn at the 50% probability level.
Table 1. Selected Bond Lengths (Å) and Bond Angles (deg)
for 1·2MeOH and 4
1·2MeOH
Pt1−O1 1.9857(18) O1−Pt1−O13 174.49(7)
Pt1−N1 2.030(2) N21−N20−Pt1 114.52(18)
Pt1−N7 2.038(2) N22−N21−N20 175.0(3)
Pt1−O13 2.0185(18) N24−N23−Pt1 113.68(18)
Pt1−N20 2.053(2) N25−N24−N23 175.6(3)
Pt1−N23 2.052(2)
N20−N21 1.211(3)
N21−N22 1.140(4)
N23−N24 1.220(3)
N24−N25 1.138(4)
4
Pt1−O1 1.969(3) O1−Pt1−O13 170.35(11)
Pt1−N1 2.030(3) N22−N21−Pt1 114.3(3)
Pt1−N7 2.033(3) N23−N22−N21 175.6(5)
Pt1−O13 2.059(3) N25−N24−Pt1 120.4(3)
Pt1−N21 2.048(4) N26−N25−N24 174.4(4)
Pt1−N24 2.052(3)
N21−N22 1.183(5)
N22−N23 1.163(6)
N24−N25 1.217(5)
N25−N26 1.137(5)
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Compared with the fully symmetrical complex FM-190,
complexes 1·2MeOH and 4 exhibit distortions from ideal
octahedral geometry. The axial bond angles between PtIV and
trans donor atoms are <180°, and the Pt−O bond [hydroxide,
1.9857(18) Å] is slightly shorter than the Pt−O bond
[succinate, 2.0185(18) Å], which can be attributed to the
steric hindrance caused by the relatively bulky carboxylate
groups. The azido ligands are almost linear, with the Pt−
N(α)−N(β) angles slightly smaller than 120°. The terminal
azide N−N bond [1.140(4) and 1.138(4) Å] is slightly shorter
than the azide N−N bond [1.211(3) and 1.220(3) Å] closest
to Pt, which is typical of the azide ligands because of their
resonance structure. The Pt−N(pyridine) bond [2.030(2) and
2.038(2) Å] is shorter than the Pt−N(azide) bond [2.053(2)
and 2.052(2) Å]. The amide CO distances are 1.240(3) and
1.236(5) Å, while those in the ester group are 1.216(3) and
1.217(4) Å, which resemble typical carbonyl groups in their
mononuclear analogues.25 Weak hydrogen bonds are observed
in complexes 1·2MeOH and 4 (Table S2 and the detailed
description in the Supporting Information).
Photoactivation. Photodecomposition of complexes 1−4
in aqueous solution was monitored by UV−vis spectroscopy at
various time intervals after irradiation with blue light (420 nm)
at ambient temperature. Figure 2 shows the decrease in the
absorbance maximum of complex 1 at ca. 300 nm, assigned as
the N3 → Pt LMCT band. The decrease indicates that release
of the azide ligands was complete within 1 h. This
photodecomposition behavior is similar to that of the
mononuclear Pt counterpart. Similar results were obtained
for the other three complexes (Figure S9). Photoreactions of
the dinuclear complex 4 were investigated by LC−MS (Figure
S10 and Table S3). The HPLC peak assigned to complex 4
disappeared within 10 min of irradiation with blue light (420
nm). Peaks assignable to dinuclear photoproducts increased in
intensity gradually, peaked after 5 min, and then decreased
over 30 min with a concomitant increase in the formation of
mononuclear photoproducts [{PtII(py)2(OC(O)H)2}+Na]
+
(m/z 466.05) and {PtII(CH3CN)(N3)(py)2}
+ (m/z 436.10).
It appears that complex 4 loses one azide from both Pt centers
initially, followed by dissociation of a Pt center and the
associated bridging ligand (Figure S10).
Formation of Azidyl Radicals. The formation of azidyl
radicals from photodecomposition of these PtIV complexes was
monitored by EPR using DMPO as a spin trap. EPR spectra
were recorded continuously for a 5 mM solution of complex 4
and 40 mM DMPO in 5% DMSO/95% water upon irradiation
with blue light (465 nm, 20 mW) at 298 K. Both azidyl and
hydroxyl radical adducts of DMPO (DMPO−N3• and
DMPO−OH•) were detected upon irradiation, as a 1:2:2:1
quartet of triplets and a 1:2:2:1 quartet, respectively (Figure
3). The simulation was carried out using the parameters listed
in Figure 3, which is in accordance with ref 23.
Photocytotoxicity and Cellular Accumulation Stud-
ies. Upon irradiation with blue light (465 nm, 4.8 mW/cm2, 1
h), complexes 1−4 exhibited photocytotoxicity toward several
human cancer cell lines, including A2780 and A2780cis ovarian
and OE19 esophageal cancer cells. The dose-dependent
inhibition of the cell viability determined by SRB colorimetric
assay both in the dark and after irradiation of complexes 1−4 is
summarized in Table 2. In parental (A2780) and cisplatin-
resistant (A2780cis) ovarian carcinoma, complexes 1−4
showed no cytotoxicity in the dark. However, upon irradiation
for 1 h, complexes 1−4 exhibited cytotoxicity to varying
extents. Complex 4 was the most potent member of the series
(IC50 = ca. 17.0 μM for ovarian cancer cells A2780 and
A2780cis and 8.8 μM for OE19) with a photocytotoxicity
index (PI) toward cancer cells of >6 for ovarian carcinoma and
11 for esophageal adenocarcinoma with light exposure.
Complexes 1 and 3 had lower IC50 values toward the
cisplatin-resistant A2780cis cell line [IC50 = 29.5 μM (1)
and 35.5 μM (3)] compared to the parental A2780 cell line
[IC50 = 77.0 μM (1) and 78.3 μM (3)], which suggests a
diﬀerent mechanism of action from cisplatin and the possibility
of overcoming the resistance. In contrast, the mononuclear
analogue FM-190 was 10 times more toxic to parental A2780
(1.4 μM) compared with cisplatin-resistant A2780cis (14.5
μM) cells upon irradiation with UVA (365 nm).21 Complexes
1−4 displayed cytotoxicity toward OE19 both in the dark and
upon irradiation. However, irradiation improved the cytotox-
icity slightly for complexes 1−3 and considerably so for 4, with
PI > 11 [IC50 = 97.0 μM (dark) and 8.8 μM (light)].
Figure 2. Photochemical decomposition of 1 [5 × 10−5 M; in 1:2 (v/
v) water/methanol] upon irradiation with blue light (420 nm)
determined by UV−vis spectroscopy. Inset: Time dependence of the
absorbance at 300 nm.
Figure 3. Observed (black) and simulated (red) EPR spectra of
complex 4 in aqueous solution with 5% DMSO showing the
formation of DMPO−N3• and DMPO−OH• adducts after irradiation
(465 nm). The experimental trace is the accumulation of 500 scans
(conversion time 5.12 ms, time constant 5.12 ms, and sweep time
10.48 s for each scan) with continuous irradiation (465 nm).
Parameters for simulation: DMPO−N3• (g = 2.00583, aNON = 14.5 mT,
aβ
H = 14.2 mT, and aNα
N = 0.31 mT); DMPO−OH• (g = 2.0058, aNON =
14.5 mT, and aβ
H = 14.2 mT).
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In contrast to the photocytotoxicity observed toward cancer
cell lines, complexes 1−4 were relatively nontoxic toward the
normal cell line MRC5, with IC50 values of >100 μM, even
after irradiation (Table 2). Because azidyl and hydroxyl
radicals generated from PtIV complexes with azides are key
species involved in cell death,23 their relative noncytotoxicity
toward MRC5 may be due to the lower basal ROS level of
healthy cells, with higher radical levels being needed to cause
cell death.41 For comparison, cisplatin tested under the same
conditions induced little cytotoxicity in all cell lines because of
the short incubation time (1 h, IC50 > 100 μM with or without
light).
Cellular accumulation is related to the molecular structure as
well as the lipophilic nature of the complex and often correlates
with the antiproliferative activity of metallodrugs. The extent of
cellular uptake of complexes 1−4 was investigated by treating
cancer cell lines with IC50 concentrations for 1 h in the dark.
The cell accumulation of Pt was then determined by ICP-MS.
As shown in Table 3, complex 3 exhibited >5 times higher Pt
accumulation than other complexes in all cell lines, attributable
to its aromatic bridge linker and higher lipophilicity. For
complexes with aliphatic linkers, 1 showed slightly higher levels
of Pt accumulation in all cancer cell lines compared with
complexes 2 and 4. It is notable that the accumulation of Pt
from complex 4 in cisplatin-resistant A2780cis ovarian cancer
cells is 2 times that for the the parental A2780 cell line, even
though complex 4 is equally toxic to both cell lines. These
results appear to support the ability of the dinuclear complexes
to overcome resistance to cisplatin.
Cell Cycle Analysis. The eﬀect of complexes 3 and 4 in the
presence of light on the progression of the cell cycle was
studied. Cells were exposed to prodrugs at equipotent
photocytotoxic IC50 concentrations for 1 h in the dark and
then irradiated for 1 h (465 nm, 4.8 mW/cm2, 1 h). After 24 h
of recovery, cells were stained in the dark with propidium
iodide in the presence of RNase and then analyzed by ﬂow
cytometry. The results are summarized in Table S4 and Figure
4.
In all cancer cell lines, the populations of cells in the stages
of the cycle were not aﬀected by the complexes in the dark but
changed dramatically upon irradiation. In OE19 esophageal
cancer cells, a reduction of cells in the G0/G1phase was
observed (ca. 45% to 29%), paralleled by an accumulation of
cells in the G2/M phases (increasing from ca. 36% to 57%),
suggesting that dinuclear complexes 3 and 4 inhibit
progression from G2/M to G0/G1 upon irradiation.
Photoactivated complex 4 induced more signiﬁcant changes
in the cell cycle progression compared with 3 (two-tail t test
with unequal variances against control; Table S4), consistent
with the higher photocytotoxicity of complex 4. Similar
changes in the cell cycle populations were found for A2780
and A2780cis ovarian cancer cells (Figure 4). This is in
contrast to cisplatin, which arrests cells in the S phase,42
suggesting a diﬀerent mechanism of action and a lack of cross-
resistance between complexes 3 and 4 and cisplatin.
Photoinduced Reactions with 5′-GMP. Because the N7
site of the DNA base guanine is a preferred target for platinum
amine anticancer complexes, photoreactions of complex 4 with
5′-GMP were investigated. The photoreactions were carried
out by irradiating solutions of complex 4 (30 μM) in 5%/95%
(v/v) methanol/water in the presence of 5′-GMP (2, 4, or 8
mol equiv) with blue light (420 nm) at 310 K and monitored
by reversed-phase HPLC (Figure S11 and Table S5). The
photorelease of the bridging ligand [HOOC(CH2)2C(O)NH-
(CH2)4NHC(O)(CH2)2COOH+H]
+ (m/z 289.21) was con-
ﬁrmed by LC−MS, and the amount released did not change
signiﬁcantly when the ratio of 5′-GMP/Pt was increased. The
major photoproduct is assignable as {PtII(CH3CN)-
(py)2(GMP-H)}
+ (m/z 756.09), which increased in propor-
tion at higher 5′-GMP ratios. In addition, two small peaks
ascribed to {PtII(N3)(py)2(GMP)}
+ (m/z 757.95) and
{PtII(OC(O)H)(py)2(GMP)}
+ (m/z 761.91) were detected.
{PtII(OC(O)H)(py)2(GMP)}
+ was formed due to the
addition of formic acid to the LC−MS mobile phase. Complex
Table 2. IC50 and PI (Photocytotoxicity Index) Values for Complexes 1−4 Obtained after 1 h of Incubation, 1 h of Irradiation
(465 nm), and 24 h of Recoverya
IC50 (μM)
b
cell 1 2 3 4 CDDP CPZ FM-190
A2780 dark >100 >100 >100 >100 >100 >100 >100
irrad 77.0 ± 2.9 33.9 ± 5.2 78.3 ± 6.8 16.7 ± 3.3 >100 6.0 ± 0.3 7.1 ± 0.4
PI >1.3 >2.9 >1.3 >6.0 >16.7 >14.0
A2780cis dark >100 >100 >100 >100 >100 51.0 ± 0.2
irrad 29.5 ± 11.0 67.6 ± 15.7 35.5 ± 3.4 17.0 ± 2.3 >100 6.0 ± 0.3
PI >3.4 >1.5 >2.8 >5.8 8.5
OE19 dark 41.3 ± 3.2 49.8 ± 1.5 53.4 ± 0.4 97.0 ± 5.7 >100
irrad 36.2 ± 2.4 27.5 ± 5.1 43.7 ± 1.9 8.8 ± 0.9 >100
PI 1.1 1.8 1.2 11.0
MRC5 dark >100 >100 >100 >100 >100 >100 >100
irrad >100 >100 >100 >100 >100 >50 >100
aCDDP (cisplatin), CPZ (chlorpromazine) and FM-190 were used as references.26,28 bThe data are from three independent experiments.
Table 3. Cell Accumulation of Pt (ng/106 cells) in Cancer
Cells after Exposure to Complexes 1−4 and FM-190
(Equipotent IC50 Concentration, 1 h, in the Dark)
a
platinum accumulation (ng/106 cells)
complex A2780 A2780cis OE19
1 24 ± 8b 17 ± 6b 13 ± 1b
2 10 ± 2b 11 ± 2c 12 ± 2c
3 101 ± 6b 56 ± 17b 51 ± 5d
4 8 ± 1b 17 ± 2b 8 ± 2b
FM-190 0.8 ± 0.2b
aAll data were determined from triplicate samples, and their statistical
signiﬁcance was evaluated by a two-tail t test with unequal variances.
bp < 0.05. cp < 0.01. dp < 0.005.
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4 reacted completely within 1 h of irradiation. The time
dependence of the formation of photoproducts from the UV−
vis spectra and LC−MS data is shown in Figure S12. Even
though decomposition of complex 4 can be detected within
only 1 min of irradiation, the apparent decrease of the
absorbance of 5′-GMP and the formation of {PtII(CH3CN)-
(py)2(GMP-H)}
+ (m/z 756.09) is observed only after 5 min of
irradiation. No dinuclear photoproduct with 5′-GMP was
detected, which suggests that the Pt centers do not react with
5′-GMP until they are detached from the bridging ligands. The
results above agree well with those previously reported for the
parent complex and its succinate derivative, suggesting that the
two PtIV centers have little eﬀect on each other during the
photoreactions with 5′-GMP.
DNA Binding Studies in Cell-Free Media. To further
explore the diﬀerences between mono- and dinuclear
complexes and the eﬀect of bridge linkers, the DNA binding
ability of photoactivated dinuclear complexes 1 and 4 was
investigated in comparison with mononuclear FM-190.
ct-DNA was mixed with complexes in 10 mM NaClO4,
immediately irradiated with blue visible light (λmax = 455 nm)
for 1 h, and then kept at 310 K in the dark. Aliquots were
removed at various time intervals and quickly ﬁltered using a
Sephadex G-50 column to remove free (unbound) Pt. The Pt
content in these DNA samples was determined by AAS, and
the concentration of DNA was determined by UV−vis to give
the kinetics of Pt binding to ct-DNA. The amount of Pt bound
to DNA increased with time for all complexes. No signiﬁcant
diﬀerence was found between the investigated complexes
(Figure 5A).
The DNA intercalator EtBr was used as a ﬂuorescent probe
to characterize perturbations induced in DNA by the adducts
with Pt complexes. Modiﬁcation of DNA by Pt complexes
under irradiation conditions resulted in a decrease of EtBr
ﬂuorescence.
The decrease caused by the adducts of photoactivated 1 or 4
was double that induced by the DNA adducts of FM-190 at
equivalent rb values (Figure 5B). It was also veriﬁed that
irradiation of ct-DNA by visible light in the absence of
complexes for 2 h had no eﬀect on EtBr ﬂuorescence. The
results of these experiments suggest that the conformational
distortions induced in DNA by the adducts formed by the
treatment of DNA with irradiated 1 and 4 are delocalized and
extended over the base pairs around the platination sites to an
extent that corresponds to the distortions induced in DNA by
two adducts of mononuclear complex FM-190. Thus, these
results are consistent with decomposition of the dinuclear
complexes 1 and 4 due to irradiation, resulting in the release of
two mononuclear fragments similar to those from FM-190.
It was shown previously43 that modiﬁcation of DNA by
irradiated FM-190 also resulted in the formation of DNA
interstrand cross-links. Therefore, we investigated the capa-
bility of irradiated 1 and 4 to form DNA interstrand cross-links
as well. Plasmid pUC19 linearized by EcoRI (50 μg mL−1) and
the Pt complex were irradiated with blue light for 1 h and
subsequently incubated in the dark for an additional 23 h in
NaClO4 (10 mM) at 310 K. The plasmid was modiﬁed to the
extent corresponding to the rb values of 0.003 and 0.0006 (in
the case of FM-190) or 0.00015 and 0.0003 (in the case of 1
and 4) and analyzed by agarose gel electrophoresis under
denaturing conditions (Figure 5C). Interstrand cross-linked
DNA appears as the top band (marked as ICLs), migrating on
the gel more slowly than single-stranded DNA (contained in
the bottom bands and marked as ss). Quantitative evaluation
Figure 4. Flow cytometry histograms showing cell cycle analysis of A2780 and A2780cis ovarian and OE19 esophageal cancer cells: pink, dark;
powder blue, irradiated. In all cases, the experiments involved 1 h of drug exposure followed by 1 h of either irradiation (465 nm) or darkness. PI =
propdium iodide.
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of the radioactivity associated with the individual bands
showed that irradiated 1 and 4 formed a 2-fold higher amount
of interstrand cross-links in DNA than FM-190 (the
frequencies of interstrand cross-linking were 12.5 ± 0.5, 24
± 2, and 24 ± 2 for FM-190, 1, and 4, respectively) at the
same level of modiﬁcation (related to the complex). Hence, the
results of DNA interstrand cross-linking experiments also
support the hypothesis that irradiation of the dinuclear
complexes 1 and 4 leads to their decomposition, resulting in
the release of two molecules similar to the photoproduct from
mononuclear complex FM-190. Our previous work suggested
that the trans-{Pt(py)2}
2+ fragment released from FM-190 can
form GG interstrand DNA cross-links, including 5′-CG/5′-CG
cross-links, 5′-GC/5′-GC cross-links, and cross-links between
G and the complementary C.44 It is, therefore, reasonable to
envisage that the treatment of DNA by irradiated dinuclear 1
or 4 results in the formation of trans GG interstrand DNA
cross-links as in the case of the treatment with mononuclear
complex FM-190.
It has been shown that the binding of various antitumor
metallodrugs to closed-circular DNA can cause partial
unfolding of the DNA. This process lowers the superhelical
density of plasmid DNA, which causes a decrease in the rate of
migration through an agarose gel. This fact makes it possible to
observe and quantify the mean value of unwinding per adduct.
In the present study, we investigated the unwinding induced in
negatively supercoiled pSP73KB plasmid by 1 and 4
photoactivated by visible light (λ = 420 nm) for 1 h and
then incubated for another 23 h at 310 K in the dark. The
degree of supercoiling was monitored using electrophoresis in
a native agarose gel. We investigated the eﬀect of increasing the
amounts of the investigated Pt complexes photoactivated by
visible light bound to a mixture of relaxed and supercoiled
pSP73KB DNA upon migration of these forms in a native
agarose gel (shown in Figure 5D). The unwinding angle is
given by Φ = −18σ/rb(c), where σ is the superhelical density
and rb(c) is the value of rb (related to the complex) at which
the supercoiled and nicked forms comigrate. The DNA
unwinding angle determined for DNA modiﬁed by dinuclear
complexes 1 and 4 photoactivated by visible light was 57 ± 8°.
This unwinding angle was 2-fold higher than that found under
identical conditions for DNA modiﬁed by mononuclear
complex FM-190 (28 ± 4°).43 Thus, consistent with the
results of the experiments aimed at characterization of the
DNA adducts by EtBr ﬂuorescence and DNA interstrand
cross-linking, the results of DNA unwinding experiments
(Figure 5D) can be interpreted to mean that the consequence
of irradiation of the dinuclear complexes 1 and 4 is their
Figure 5. DNA binding of photoactivated complexes in cell-free media. (A) Kinetics of the reaction of the investigated complexes photoactivated
by visible light (λmax = 455 nm) with ct-DNA. For other details, see the text. (B) Dependence of ethidium bromide ﬂuorescence on rb for double-
helical ct-DNA modiﬁed by the investigated Pt complexes photoactivated by visible light (λmax = 455 nm) in NaClO4 (10 mM) at 37 °C for 24 h.
(C) Formation of interstrand (intramolecular) cross-links by the investigated Pt complexes photoactivated by visible light (λmax = 455 nm) in
pUC19 plasmid linearized by EcoRI. Solutions of the linearized plasmid (50 μg mL−1) were incubated with the Pt complex under irradiation
conditions (for 1 h and subsequently incubated in the dark for an additional 23 h) at various ri values in NaClO4 (10 mM) at 37 °C. The
autoradiogram of denaturing 1% agarose gel of linearized DNA which was 3′-end-labeled and nonmodiﬁed and nonirradiated (kept in the dark;
lane C) or modiﬁed by photoactivated FM-190 (rb = 0.0003 and 0.0006 for lanes 1 and 2, respectively), 1 (rb = 0.00015 and 0.0003 for lanes 3 and
4, respectively), or 4 (rb = 0.00015 and 0.0003 for lanes 3 and 4, respectively). Interstrand cross-linked DNA appears as the top bands (marked as
ICL), migrating on the gel more slowly than single-stranded DNA (contained in the bottom bands and marked as ss). (D) Unwinding of
supercoiled pSP73KB plasmid DNA by the investigated dinuclear Pt complexes photoactivated by visible light (λmax = 455 nm). The top bands
correspond to the nicked form of the plasmid and the bottom bands to the closed, negatively supercoiled plasmid. The plasmid was incubated with
FM-190, 1, and 4 under irradiation conditions (for 1 h and subsequently incubated in the dark for an additional 23 h) at various ri values in
NaClO4 (10 mM) at 37 °C. Lane C: control, nonplatinated, and nonirradiated DNA (rb = 0). Lanes 1−10: DNA modiﬁed by photoactivated
complexes so that the resulting rb values were, for FM-190, 0.001, 0.003, 0.005, 0.010, 0.015, 0.020, 0.025, 0.030, 0.035, and 0.040, respectively, for
1, 0.0005, 0.0025, 0.005, 0.0075, 0.01, 0.0125, 0.015, 0.0175, 0.02, and 0.025, respectively, and for 4, 0.001, 0.0015, 0.0025, 0.0035, 0.005, 0.01,
0.015, 0.0175, and 0.02, respectively.
Inorganic Chemistry Article
DOI: 10.1021/acs.inorgchem.8b02599
Inorg. Chem. 2018, 57, 14409−14420
14417
decomposition, resulting in the release of two molecules of
mononuclear complex FM-190.
A parameter that makes identiﬁcation of the preferential
DNA binding sites of Pt antitumor drugs possible can be
obtained from transcription mapping experiments.45 In vitro
RNA synthesis by RNA polymerases on DNA templates
containing several types of bifunctional adducts of Pt
complexes can be prematurely terminated at the level, or in
the proximity, of DNA adducts. We prepared a 212-bp
fragment by the cutting of pSP73KB DNA by NdeI and HpaI
restriction endonucleases. A substantial part of its nucleotide
sequence is shown in Figure S13B. This fragment contained a
T7 RNA polymerase promotor (in the upper strand close to its
3′ end; Figure S13B). The experiments were carried out using
this linear DNA fragment, modiﬁed by cisplatin, transplatin (in
the dark), or 1 or 4 photoactivated by visible light. The
samples were irradiated for 1 h and subsequently incubated in
the dark for an additional 23 h. The rb values were in the range
of 0.004−0.01 and are indicated in the legend to Figure S13A.
The major stop signals for DNA modiﬁed by dinuclear
complexes 1 and 4 (Figure S13) were identical with those
found previously under identical conditions for DNA modiﬁed
by irradiated FM-190.43
In order to obtain further information on the sequence
speciﬁcity of DNA binding in the dinuclear 1 and 4 analogues
of complex FM-190, a DNase I footprinting experiment was
also performed (Figure S14). The details of this experiment are
described in the Supporting Information. The results show that
the preferential binding sites of dinuclear complexes 1 and 4
are those containing mainly G/A-rich sequences and are
identical with those of mononuclear complex FM-190.
Collectively, the results of transcription mapping and DNase
I footprinting experiments suggest that preferential DNA
binding sites of irradiated dinuclear complexes 1 and 4 are
similar to those of mononuclear complex FM-190, thus also
supporting the hypothesis that irradiation of the dinuclear
complexes 1 and 4 results in their decomposition, resulting in
the release of two molecules similar to the photoproducts from
mononuclear complex FM-190.
■ CONCLUSIONS
We report the synthesis and characterization of a series of
novel dinuclear photoactive PtIV anticancer prodrugs trans,-
trans,trans-[{Pt(N3)2(py)2(OH)(OC(O)CH2CH2C(O)-
NH)}2R] containing pyridine (py) and bridging dicarboxylate
[R = −CH2CH2− (1), trans-1,2-C6H10− (2), p-C6H4− (3),
−CH2CH2CH2CH2− (4)] ligands. We compared their
photoreactivity with that of a mononuclear analogue FM-
190. Azidyl and hydroxyl radicals and PtII species were
generated during photodecomposition of these dinuclear
complexes. LC−MS analyses of photoreactions of dinuclear
complex 4 revealed the photorelease of the bridging ligand and
the formation of mononuclear photoproducts. In the presence
of 5′-GMP, the PtII-5′-GMP adduct {PtII(CH3CN)-
(py)2(GMP-H)}
+ (756.09) was formed upon irradiation.
Dinuclear complexes exhibited promising photocytotoxicity
upon irradiation with low-dose blue light (465 nm, 4.8 mW/
cm2, 1 h) toward a series of human cancer cell lines, including
A2780, A2780cis, and OE19, with high dark stability.
Moreover, the dinuclear complexes were remarkably nontoxic
toward normal cells (MRC5), even after irradiation. The
introduction of an aromatic bridging ligand signiﬁcantly
enhanced cell uptake for complex 3 compared with the
complexes containing an aliphatic bridge. The inhibition of
progression from G2/M to G0/G1 stages in the cell cycle
induced by dinuclear complexes upon irradiation suggests that
DNA is a target. The dinuclear complexes behaved in cell-free
media and after photoactivation similarly to the photoactivated
mononuclear complex FM-190 in terms of the kinetics of
binding to ct-DNA, transcription mapping, and DNase I
footprinting of Pt-DNA adducts. However, dinuclear com-
plexes after photoactivation were approximately 2-fold more
eﬀective in quenching the ﬂuorescence of EtBr bound to DNA,
forming DNA interstrand cross-links, and unwinding DNA
compared to the photoactivated mononuclear Pt analogue FM-
190. This is consistent with photodecomposition of the
dinuclear complexes into two molecules of mononuclear PtII
species.
Hence, dinuclear complexes exhibit promising dark stability,
photocytotoxicity, and selectivity toward cancer cells, depend-
ent on the nature of the bridging ligand.
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(14) Müller, P.; Schröder, B.; Parkinson, J. A.; Kratochwil, N. A.;
Coxall, R. A.; Parkin, A.; Parsons, S.; Sadler, P. J. Nucleotide cross-
linking induced by photoreactions of platinum(IV)-azide complexes.
Angew. Chem., Int. Ed. 2003, 42, 335−339.
(15) Mackay, F. S.; Woods, J. A.; Heringova,́ P.; Kasp̌aŕkova,́ J.;
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platinum(IV) anticancer complex conjugated to the RNA ligand
Guanidinoneomycin. Chem. - Eur. J. 2015, 21, 18474−18486.
(26) Venkatesh, V.; Wedge, C. J.; Romero-Canelo ́n, I.;
Habtemariam, A.; Sadler, P. J. Spin-labelled photo-cytotoxic diazido
platinum(IV) anticancer complex. Dalton Trans. 2016, 45, 13034−
13037.
(27) Min, Y.; Li, J.; Liu, F.; Yeow, E. K. L.; Xing, B. Near-infrared
light-mediated photoactivation of a platinum antitumor prodrug and
simultaneous cellular apoptosis imaging by upconversion-luminescent
nanoparticles. Angew. Chem., Int. Ed. 2014, 53, 1012−1016.
(28) Venkatesh, V.; Mishra, N. K.; Romero-Caneloń, I.; Vernooij, R.
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